SciELO - Scientific Electronic Library Online

 
vol.11 issue1Prolonged QTc interval in patients of Clinical Medicine: multicenter studyFrequency of risk factors for the development of prediabetes in health workers author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Virtual de la Sociedad Paraguaya de Medicina Interna

On-line version ISSN 2312-3893

Abstract

CABALLERO TORRES, Marlene Elizabeth et al. Monotherapy versus combination therapy as treatment of multidrug-resistant Acinetobacter baumannii infections. Rev. virtual Soc. Parag. Med. Int. [online]. 2024, vol.11, n.1, e11122413.  Epub June 20, 2024. ISSN 2312-3893.  https://doi.org/10.18004/rvspmi/2312-3893/2024.e11122413.

Introduction:

Acinetobacter baumannii is associated with high morbidity and mortality, longer hospital stays, and, therefore, a great health impact.

Objectives:

To compare the clinical response and survival using intravenous colistin as antibiotic treatment versus colistin combined with high doses of ampicillin/sulbactam in multidrug-resistant A. baumannii infections in the adult intensive care units of the National Hospital (Itauguá, Paraguay).

Materials and methods:

A retrospective cohort design was applied to analyze the clinical and laboratory response, 14-day survival, and mortality rate in patients treated with colistin five mg/kg/day as monotherapy versus combined colistin therapy five mg/kg/day plus ampicillin/sulbactam 9 grams four times a day. The variables were obtained from the clinical records of patients ≥18 years old infected with multidrug-resistant A. baumannii.

Results:

One hundred sixty-three patients were included, with a mean age of 50 ± 17 years, 61.96% male. Pneumonia associated with mechanical ventilation was present in 69.33%, bacteremia in 21.47%, ventriculitis in 5.52% and infections related to the central venous line in 3.68%. A cohort of 88 patients received monotherapy with intravenous colistin and another of 75 patients received combined therapy with intravenous colistin plus high doses of ampicillin/sulbactam. No differences were found in the APACHE II score between both cohorts. The cohort with combined treatment demonstrated statistically significant superiority by presenting clinical and laboratory improvement at 72 hours, less need for vasopressors, better survival at 14 days, and less nephrotoxicity. The overall mortality rate was 45.40%.

Conclusion:

The combined therapy of intravenous colistin with high doses of ampicillin/sulbactam in prolonged infusion was related to early clinical improvement, shorter time requiring vasopressors and mechanical ventilation, greater survival at 14 days, and less nephrotoxicity.

Keywords : Acinetobacter baumannii; colistin; ampicillin; sulbactam; bacterial drug resistance.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )